ACUT

AccuStem Sciences, Inc.

Price Chart

Latest Quote

$0.36

+0.10 (+38.27%)

Current Price

Previous Close	$0.26
Open	$0.26
Day High	$0.26
Day Low	$0.26
Volume	400

Fetched: 2026-06-04T20:29:07

Stock Information

Shares Outstanding	16.07M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$5.72M
EPS (TTM)	$-0.12
Exchange	OQB

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Book/sh	$-0.21
Employees	4

Financial Ratios

Returns & Margins

Ownership

Insider Ownership	50.92%
Insider & Institutional transactions data not available

Valuation Ratios

P/B

-1.68

Analyst Data

Recommendation

none

Technical Indicators

SMA20	$0.27
SMA50	$0.31
SMA200	$0.82
RSI	89.60
ATR	0.0122

Rel Volume

0.11

Performance History

Week	+38.27%
Month	+27.16%
Quarter	-19.08%
6 Months	-56.58%
YTD	-56.23%
Year	-31.53%
3 Years	-51.23%
10 Years	-82.20%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-03	$0.36	158
2026-06-02	$0.26	0
2026-06-01	$0.26	0
2026-05-29	$0.26	0
2026-05-28	$0.26	0
2026-05-27	$0.26	720
2026-05-26	$0.26	2,073
2026-05-22	$0.27	0
2026-05-21	$0.27	0
2026-05-20	$0.27	0
2026-05-19	$0.27	0
2026-05-18	$0.27	23,073
2026-05-15	$0.26	0
2026-05-14	$0.26	0
2026-05-13	$0.26	0
2026-05-12	$0.26	249
2026-05-11	$0.26	1,279
2026-05-08	$0.31	0
2026-05-07	$0.31	117
2026-05-06	$0.28	0
2026-05-05	$0.28	0

About AccuStem Sciences, Inc.

AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. The company offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. It also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. AccuStem Sciences, Inc. was founded in 2013 and is headquartered in New York, New York.

📰 Latest News

No news articles available at the moment. Check back later for updates on ACUT.

Period:

Income Statement (Annual)

Metric	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0
Operating Revenue	$0	$0	$0
Expenses
Total Expenses	$1,505,102	$2,050,664	$3,746,419
Operating Expense	$1,505,102	$2,050,664	$3,746,419
General And Administrative Expense	$1,366,778	$1,911,001	$3,479,486
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-1,505,102	$-2,050,664	$-3,746,419
Normalized Income	$-1,505,102	$-2,050,664	$-3,746,419
Net Income From Continuing And Discontinued Operation	$-1,505,102	$-2,050,664	$-3,746,419
Total Operating Income As Reported	$-1,505,102	$-2,050,664	$-3,746,419
Net Income Common Stockholders	$-1,505,102	$-2,050,664	$-3,746,419
Net Income	$-1,505,102	$-2,050,664	$-3,746,419
Net Income Including Noncontrolling Interests	$-1,505,102	$-2,050,664	$-3,746,419
Net Income Continuous Operations	$-1,505,102	$-2,050,664	$-3,746,419
Pretax Income	$-1,505,102	$-2,050,664	$-3,746,419
Operating Income	$-1,505,102	$-2,050,664	$-3,746,419
Per Share
Diluted EPS	$-0.13	$-0.18	$-0.34
Basic EPS	$-0.13	$-0.18	$-0.34
Other
Tax Effect Of Unusual Items	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-1,501,472	$-2,047,034	$-3,743,098
Reconciled Depreciation	$3,630	$3,630	$3,321
EBITDA (Bullshit earnings)	$-1,501,472	$-2,047,034	$-3,743,098
EBIT	$-1,505,102	$-2,050,664	$-3,746,419
Diluted Average Shares	$11,435,362	$11,346,535	$11,016,165
Basic Average Shares	$11,435,362	$11,346,535	$11,016,165
Diluted NI Availto Com Stockholders	$-1,505,102	$-2,050,664	$-3,746,419
Tax Provision	$0	$0	$0
Research And Development	$138,324	$139,663	$266,933
Selling General And Administration	$1,366,778	$1,911,001	$3,479,486
Other Gand A	$1,366,778	$1,911,001	$3,479,486

Fetched: 2026-02-02

Balance Sheet (Annual)

Metric	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$-3,313,224	$-2,111,580	$-139,550
Total Assets	$50,851	$133,897	$939,689
Total Non Current Assets	$418	$4,048	$7,678
Current Assets	$50,433	$129,849	$932,011
Prepaid Assets	$45,387	$108,368	$168,430
Cash Cash Equivalents And Short Term Investments	$5,046	$21,481	$733,978
Cash And Cash Equivalents	$5,046	$21,481	$733,978
Cash Financial	$5,046	$21,481	$733,978
Other Current Assets	-	-	$29,603
Debt
Net Debt	$20,102	$34,198	-
Total Debt	$25,148	$55,679	$106,551
Current Debt And Capital Lease Obligation	$25,148	$55,679	$106,551
Current Debt	$25,148	$55,679	$106,551
Liabilities
Total Liabilities Net Minority Interest	$3,364,075	$2,245,477	$1,079,239
Total Non Current Liabilities Net Minority Interest	$0	$0	$0
Current Liabilities	$3,364,075	$2,245,477	$1,079,239
Current Notes Payable	$25,148	$55,679	$106,551
Payables And Accrued Expenses	$3,338,927	$2,189,798	$972,688
Payables	$3,174,874	$2,033,364	$454,063
Accounts Payable	$804,615	$578,378	$311,834
Equity
Common Stock Equity	$-3,313,224	$-2,111,580	$-139,550
Total Equity Gross Minority Interest	$-3,313,224	$-2,111,580	$-139,550
Stockholders Equity	$-3,313,224	$-2,111,580	$-139,550
Retained Earnings	$-8,027,047	$-6,521,945	$-4,471,281
Other
Ordinary Shares Number	$12,100,535	$11,346,535	$11,346,535
Share Issued	$12,100,535	$11,346,535	$11,346,535
Tangible Book Value	$-3,313,224	$-2,111,580	$-139,550
Invested Capital	$-3,288,076	$-2,055,901	$-32,999
Working Capital	$-3,313,642	$-2,115,628	$-147,228
Total Capitalization	$-3,313,224	$-2,111,580	$-139,550
Additional Paid In Capital	$4,701,723	$4,399,019	$4,320,385
Capital Stock	$12,100	$11,346	$11,346
Common Stock	$12,100	$11,346	$11,346
Preferred Stock	$0	$0	$0
Current Accrued Expenses	$164,053	$156,434	$518,625
Dueto Related Parties Current	$2,370,259	$1,454,986	$142,229
Net PPE	$418	$4,048	$7,678
Accumulated Depreciation	$-10,581	$-6,951	$-3,321
Gross PPE	$10,999	$10,999	$10,999
Machinery Furniture Equipment	$10,999	$10,999	$10,999
Treasury Shares Number	-	$0	-

Fetched: 2026-02-02

Cash Flow Statement (Annual)

Metric	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-664,066	$-1,615,643	$-1,817,052
Operating Activities
Operating Cash Flow	$-664,066	$-1,615,643	$-1,806,053
Cash Flow From Continuing Operating Activities	$-664,066	$-1,615,643	$-1,806,053
Operating Gains Losses	-	-	$-66,981
Investing Activities
Investing Cash Flow	$0	$0	$-10,999
Cash Flow From Continuing Investing Activities	$0	$0	$-10,999
Capital Expenditure	-	-	$-10,999
Financing Activities
Issuance Of Capital Stock	$0	$0	$2,675,940
Financing Cash Flow	$647,632	$903,146	$2,551,030
Cash Flow From Continuing Financing Activities	$647,632	$903,146	$2,551,030
Net Other Financing Charges	$781,077	$1,246,757	$204,879
Net Common Stock Issuance	$0	$0	$2,675,940
Common Stock Issuance	$0	$0	$2,675,940
Other
Repayment Of Debt	$-133,445	$-343,611	$-338,258
Interest Paid Supplemental Data	$3,392	$7,192	$7,474
End Cash Position	$5,047	$21,481	$733,978
Beginning Cash Position	$21,481	$733,978	$0
Changes In Cash	$-16,434	$-712,497	$733,978
Proceeds From Stock Option Exercised	$0	$0	$8,469
Net Issuance Payments Of Debt	$-133,445	$-343,611	$-338,258
Net Short Term Debt Issuance	$-133,445	$-343,611	$-338,258
Short Term Debt Payments	$-133,445	$-343,611	$-338,258
Net PPE Purchase And Sale	$0	$0	$-10,999
Purchase Of PPE	$0	$0	$-10,999
Change In Working Capital	$533,948	$352,757	$1,870,137
Change In Other Current Assets	$0	$29,603	$-29,603
Change In Payables And Accrued Expense	$368,053	$-19,968	$275,675
Change In Accrued Expense	$7,620	$-352,512	$401,130
Change In Payable	$360,433	$332,544	$-125,455
Change In Account Payable	$226,237	$266,544	$-76,846
Change In Prepaid Assets	$165,895	$343,122	$270,692
Change In Receivables	$0	$0	$1,353,373
Stock Based Compensation	$303,458	$78,634	$133,889
Depreciation Amortization Depletion	$3,630	$3,630	$3,321
Depreciation And Amortization	$3,630	$3,630	$3,321
Depreciation	$3,630	$3,630	$3,321
Net Income From Continuing Operations	$-1,505,102	$-2,050,664	$-3,746,419
Net Foreign Currency Exchange Gain Loss	-	$0	$-66,981

Fetched: 2026-02-02